Your browser doesn't support javascript.
loading
Hypothyroidism, comorbidity and health-related quality of life: a population-based study.
Wouters, Hanneke J C M; Wolffenbuttel, Bruce H R; Muller Kobold, Anneke C; Links, Thera P; Huls, Gerwin; van der Klauw, Melanie M.
Afiliação
  • Wouters HJCM; Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Wolffenbuttel BHR; Department of Hematology, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Muller Kobold AC; Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Links TP; Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Huls G; Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands.
  • van der Klauw MM; Department of Hematology, University of Groningen, University Medical Center Groningen, The Netherlands.
Endocr Connect ; 12(12)2023 Dec 01.
Article em En | MEDLINE | ID: mdl-37855378
Hypothyroidism is associated with a decreased health-related quality of life (HRQoL). We hypothesized that individuals with hypothyroidism (defined as use of thyroid hormone (TH)) and especially those having an impaired HRQoL are characterized by a high prevalence of comorbid disorders and that the impact of hypothyroidism and comorbidity on HRQoL is synergistic. Presence of comorbidity was based on data obtained using structured questionnaires, physical examination, biochemical measurements and verified medication use. Single morbidities were clustered into 14 different disease domains. HRQoL was measured using the RAND-36. Logistic regression analyses were used to determine the effect of TH use on the odds of having an affected disease domain and a lower score than an age- and sex-specific reference value for HRQoL. TH was used by 4537/14,7201 participants of the population-based Lifelines cohort with a mean (± s.d.) age of 51.0 ± 12.8 years (88% females). Eighty-five percent of the TH users had ≥1 affected disease domain in contrast to 71% of nonusers. TH use was associated with a higher odds of 13 out of 14 affected disease domains independent of age and sex. In a multivariable model, TH use was associated with a decreased HRQoL across six out of eight dimensions. No significant interactions between TH use and affected disease domains were observed. TH users with an impaired HRQoL had significantly more comorbidity than those not having an impaired HRQoL. In this large, population-based study, we demonstrated that TH users had more comorbidity than individuals not using TH. The coexistence of other chronic medical conditions in subjects with TH use led to further lowering of HRQoL in an additive manner.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Endocr Connect Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Endocr Connect Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda